Ivonescimab (AK112) + Chemotherapy
Metastatic Non-Squamous NSCLC (1L, no actionable mutations)
Key Facts
About Summit Therapeutics
Summit Therapeutics' mission is to develop and commercialize innovative medicines for serious unmet medical needs, with a strategic focus on oncology and infectious diseases. Its key achievement is the advancement of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, into pivotal Phase III trials for non-small cell lung cancer (NSCLC). The company's strategy combines strategic asset acquisition with focused clinical development to build value through high-potential, late-stage programs. Summit's significant market valuation reflects investor confidence in its lead asset's differentiated profile and blockbuster potential.
View full company profileAbout Summit Therapeutics
Summit Therapeutics' mission is to develop and commercialize innovative medicines for serious unmet medical needs, with a strategic focus on oncology and infectious diseases. Its key achievement is the advancement of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, into pivotal Phase III trials for non-small cell lung cancer (NSCLC). The company's strategy combines strategic asset acquisition with focused clinical development to build value through high-potential, late-stage programs. Summit's significant market valuation reflects investor confidence in its lead asset's differentiated profile and blockbuster potential.
View full company profileAbout Summit Therapeutics
Summit Therapeutics' mission is to develop and commercialize innovative medicines for serious unmet medical needs, with a strategic focus on oncology and infectious diseases. Its key achievement is the advancement of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, into pivotal Phase III trials for non-small cell lung cancer (NSCLC). The company's strategy combines strategic asset acquisition with focused clinical development to build value through high-potential, late-stage programs. Summit's significant market valuation reflects investor confidence in its lead asset's differentiated profile and blockbuster potential.
View full company profile